Envoy Medical Q1 revenue down $13k; enrolls 10 in pivotal CI trial; secures $10M funding

Envoy Medical, Inc.

2025-Q1 EPS reported -$0.29 vs consensus -$0.35 ▲ beat (+16.4%)

Net revenues decreased $13k YoY to an undisclosed amount; cash balance $5.3M as of March 31, 2025.
R&D expenses rose $400k YoY due to headcount and clinical study startup for Acclaim cochlear implant.
Enrolled 10 participants in first stage of pivotal clinical trial for fully implanted Acclaim CI; 6 activated.
Secured additional $10M in funding to advance pivotal clinical trial; no serious adverse events reported.
Modifications appear to address electrical system noise observed in earlier feasibility study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.